Background-The role of the adenosine 5Ј-diphosphate receptor P2Y 12 in platelet activation initiated by the von Willebrand factor (VWF)-GP Ib␣ interaction under high shear rate was investigated. Methods and Results-Blood samples were obtained from 11 donors. Shear-induced platelet aggregation was detected by optically modified cone-plate viscometer. Shear-induced VWF binding, P-selectin expression, and microparticle release were detected by flow cytometry. Platelet interaction with immobilized VWF was also investigated by parallel-plate flow chamber equipped with epifluorescent videomicroscopy. Effects of a selective P2Y 12 antagonist AR-C69931 MX were tested. AR-C69931 MX inhibited shear-induced platelet aggregation in a dose-dependent manner, achieving the maximum inhibition at 100 nmol/L. The extent of aggregation after exposure to a shear rate of 10 800 s Ϫ1 for 6 minutes in the presence of 100 nmol/L AR-C69931 MX was 32.4Ϯ8.2% (meanϮSD), which was significantly lower than the value in the controls of 69.7Ϯ9.6% (PϽ0.01). The inhibiting effects of AR-C69931 MX were reversed by exogenous addition of adenosine 5Ј-diphosphate. Shear-induced VWF binding and P-selectin surface translocation, which occurred in 4696Ϯ911 and 5964Ϯ784, respectively, of 10 000 measured platelets, was also inhibited by AR-C69931 MX (100 nmol/L) to 1948Ϯ528 and 2797Ϯ718, respectively (Pϭ0.0018 and Pϭ0.0009). Microparticle release was similarly inhibited. In a flow chamber experiment, firm platelet attachment on immobilized VWF was inhibited by AR-C69931 MX, whereas transient interaction was not influenced. All the above reactions were completely inhibited by blocking VWF-GP Ib␣ interaction. Conclusions-We have demonstrated that the stimulation of P2Y 12 is involved in platelet activation initiated by the binding of VWF to GP Ib␣ induced by a high shear rate. (Circulation. 2002;105:2531-2536.)
R ecent investigations have revealed that the antiplatelet effects of thienopyridine antiplatelet agents such as ticlopidine and clopidogrel depend on the specific and irreversible inhibition of platelet adenosine 5Ј-diphosphate (ADP) receptors coupled with Gi/adenylate cyclase (P2T AC ), 1 recently cloned as P2Y 12 2 by their active metabolites. 3 Although 3 different ADP receptors mediating different cellular reactions of platelets have been cloned so far 4 (eg, P2X 1 , which mediates calcium influx, 5 P2Y 1 , which mediates intracellular calcium mobilization, 5 and P2Y 12 , a Gi-coupled receptor mediating the action of adenylate cyclase 2, 4, 5 and other more complex signaling that has yet to be clarified, 6, 7 ) , understanding the role played by P2Y 12 receptors is particularly important since large-scale randomized clinical studies have shown the effectiveness of thienopyridine antiplatelet agents in preventing arterial thrombotic disease. 8, 9 Many reports indicate that P2Y 12 stimulation by exogenously added ADP is crucial for platelet activation and aggregation in vitro. 2, 4, 5, 10, 11 However, the important issue-why in vivo arterial thrombosis was prevented by its inhibition-is still not fully understood.
Recent investigation revealed that von Willebrand factor (VWF) and its interaction with platelet receptor proteins GP Ib␣ and GP IIb/IIIa played an important role in the onset of platelet thrombosis at sites exposed to high shear rates. [12] [13] [14] In this study, we attempted to clarify the role of the P2Y 12 receptor inhibition in VWF-mediated platelet activation and aggregation under high shear stress by using the specific P2Y 12 antagonist AR-C69931 MX. 15 
Methods

Preparation of Platelet Samples
Platelet-rich plasma was separated by centrifugation of blood specimens anticoagulated by citrate (0.38%), obtained from healthy adult donors who abstained from drugs known to interfere with platelet function (such as nonsteroidal antiinflammatory drugs) for at least 4 weeks. Additional blood samples obtained for the flow experiments were anticoagulated by the specific antithrombin agent Argatroban (Mitsubishi Kagaku Co) at a final concentration of 100 mol/L.
Shear-Induced Platelet Aggregation, VWF Binding to Platelets, and Platelet Activation
Platelet aggregation under a selected shear rate can be measured with the use of an optically modified cone-plate viscometer as described previously. 14, 16, 17 Effects of AR-C69931 MX was tested at 10 800 s Ϫ1 because a previous study demonstrated VWF binding with both GP Ib␣ and GP IIb/IIIa was required to induce aggregation at that high shear rate. 17 Laser light transmittance of the sample was measured continuously while the samples were exposed to a shear field, and the measured light transmittance, which was converted to the level of platelet aggregation based on the Lambert-Beer equation, was stored in a computer (PC-9800CX, NEC). 17 Shear-induced VWF binding and subsequent activation with P-selectin surface translocation was detected by flow cytometry with FITC-conjugated specific anti-VWF (LJ-C3, provided by Dr Zaverio M. Ruggeri from the Scripps Research Institute) 18 and anti-Pselectin (WGA1) monoclonal antibody. 19 Two other agents, FITCconjugated anti-GP Ib␣ (LJ-P3, also provided by Dr Zaverio) 18 and FITC-conjugated Annexin V, which bind to phopholipid-rich procoagulant surfaces, 20 were used to detect platelet-derived microparticles. LJ-P3 was used because it did not compete with VWF binding to GP Ib␣. 21 Shear-induced microparticle release was calculated as the difference between samples exposed to the shear forces and control samples that were not exposed.
Platelet Interaction With Immobilized VWF Under Flow Conditions
Human purified VWF was immobilized on glass coverslips (Corning, Inc; 24ϫ50 mm) in a parallel-plate flow chamber, as described previously. 22, 23 Then, whole blood containing platelets rendered fluorescent by mepacrine was pumped through the chamber with a syringe pump at a constant flow rate to achieve a wall shear rate of 1500 s Ϫ1 . Platelets interacting with immobilized VWF were visualized under an inverted-stage epifluorescence videomicroscope equipped with a 480-nm excitation light source (DM IRB, 1RB-FLUO, Leica). 23 The microscopic images were digitized on-line with a photosensitive color CCD camera (L-600, Leica) and stored as digital images in a personal computer (Power Macintosh G3, Apple Co, Ltd). The effects of AR-C69931 MX on platelet-VWF surface interaction was qualitatively demonstrated by overlaying 60 consecutive frames of the video images (corresponding to 2 seconds), so that firmly attached platelets that did not move appeared as thick images, whereas moving (eg, rolling) platelets, which appeared in only some of the frames, appeared as thinner images. The movement of every single platelet appearing in the consecutive image frames was quantified.
Reagents Used in Experiments
AR-C69931 MX, a specific inhibitor of P2Y 12 , was kindly provided by AstraZeneca R&D Charnwood (Loughborough, Leicestershire, England). The basic characteristics of the material have been described elsewhere. 15 FITC-conjugated PAC-1 and its binding to ADP-activated GP IIb/IIIa were detected by flow cytometry. 24 This assay was used to characterize AR-C69931 MX. LJ-Ib1, the antibody blocking the binding of VWF to GP Ib␣, was also kindly provided by Dr Zaverio. This antibody is known to block shear-induced binding of VWF to GP Ib␣ to generate a negative control. 18
Statistical Analysis
All numerical data are expressed as meanϮSD unless otherwise specified. The effect of various concentrations of AR-C69931 MX on platelet aggregation and activation was tested by 1-way ANOVA. Differences between two groups of data were compared by Fisher analysis. Statistical significance of the difference between two groups of data was tested by Student's paired t test. A value of PϽ0.05 was considered to be statistically significant.
Results
Effects of AR-C69931 MX on Shear-Induced Platelet Aggregation
AR-C69931 MX inhibited shear-induced platelet aggregation in a dose-dependent manner at concentrations Ͼ5 nmol/L ( Figure 1) , with the maximum inhibition achieved at 100 nmol/L. The extent of aggregation after exposure to a shear rate of 10 800 s Ϫ1 for 6 minutes in the presence of 100 nmol/L AR-C69931 MX was 32.4Ϯ8.2% (meanϮSD), which was significantly lower than that in the absence of the agent of 69.7Ϯ9.6% (PϽ0.01). At relatively low concentrations, that is, Ͻ1 nmol/L, diaaggregation occurred, although the maximum extent of aggregation was not influenced. The aggregation observed under the tested shear rate was mediated by the interaction of VWF with GP Ib␣, since it was completely inhibited by an antibody that would block this interaction (LJ-Ib1) ( Figure 1 ). The inhibiting effect of AR-C69931 MX on the shear-induced aggregation was mediated by its competition for the P2Y 12 receptor with ADP, since its inhibiting effects could be reversed by exogenous addition of ADP, as shown in Figure 2 . Receptor competition between ADP and AR-C6993 MX was confirmed by a simple ADP-induced platelet activation assay, as shown in Figure 3 . The inhibitory effects of AR-C69931 MX on ADP-induced platelet activation, as evidenced by the PAC-1 binding, was overcome by addition of extremely high concentrations of ADP.
Effects of AR-C69931 MX on Shear-Induced Platelet Activation
Of 10 000 platelets measured, shear-induced VWF binding and P-selectin translocation occurred in 4296Ϯ911 and 5964Ϯ784 platelets, respectively ( Figure 4 ). Mean numbers of anti-VWF and anti-P-selectin antibodies binding to single platelets increased from 294.6Ϯ49.1 per platelet and 43.4Ϯ46.0 per platelet before shearing to 1369.4Ϯ318.8 per platelet and 1821Ϯ814 per platelet after shearing, respectively (Pϭ0.0015 and Pϭ0.0071, respectively). Plateletderived microparticles, measured as particles with GP Ib␣ and those with procoagulant activity detected by annexin V binding, also increased from 1663Ϯ1021 and 1023Ϯ445 before shearing to 16744Ϯ6903 and 9745Ϯ3832 after shearing, respectively (Pϭ0.0030 and Pϭ0.022). The shearinduced VWF binding and subsequent platelet activation evidenced by P-selectin surface translocation and microparticle release were inhibited by AR-C69931 MX in a dosedependent manner (Figure 4 ). Shear-induced VWF binding, P-selectin surface translocation, and microparticle release were inhibited at 65.9Ϯ17.3, 68.5Ϯ16.0, and 65.4Ϯ11.6 (%), respectively, with 100 nmol/L AR-C69931 MX, whereas 95.4Ϯ4.6, 93.5Ϯ5.6, and 89.5Ϯ9.0 (%) of those reactions could be inhibited by the monoclonal antibody capable of blocking the binding of VWF to GP Ib␣ ( Figure 5 ). Mean numbers of anti-VWF and anti-P-selectin antibodies binding to single platelets still increased from 233.6Ϯ50.0 and 10.7Ϯ33.4 before shearing to 463.3Ϯ92.1 and 282.1Ϯ192.6 after shearing, even in the presence of 100 nmol/L AR-C69931 MX, respectively (Pϭ0.0028 and Pϭ0.020, respectively).
Effects of AR-C69931 MX on Platelet Interaction With Immobilized VWF in Whole Blood Experiments
Firm platelet attachment on immobilized VWF occurring under a wall shear rate of 1500 s Ϫ1 was inhibited by AR-C69931 MX at a dose maximally inhibiting shear- 
Discussion
We have demonstrated that Ͼ50% of platelet activation and aggregation caused by the interaction of VWF with platelet GP Ib␣ under conditions of high shear rate in platelet-rich plasma could be inhibited by blocking the action of P2Y 12 by AR-C69931 MX. We also demonstrated that firm platelet attachment on immobilized VWF in whole blood, presumably mediated by VWF binding to activated GP IIb/IIIa, is inhibited by AR-C69931 MX, suggesting the role of P2Y 12 in VWF-mediated platelet activation in whole blood, too. These results, along with previously published findings demonstrating the involvement of VWF-mediated platelet thrombosis in animal arterial thrombosis models 12, 13 or ex vivo human studies, 14,16 -19,25-28 strongly suggest the importance of P2Y 12 stimulation in the process of arterial thrombosis. Our present findings provide experimental evidence explaining the mechanism of in vivo antithrombotic action of P2Y 12 inhibition achieved by thienopyridine antiplatelet agents such as ticlopidine and clopidogrel in the absence of exogenous addition of ADP. In addition, our results provide important experimental evidence showing that blocking P2Y 12 stimulation by ADP released from platelets abrogates Ͼ50% of platelet reaction initiated by VWF-GP Ib␣ interaction.
Our findings with the specific P2Y 12 antagonist AR-C69931 MX on shear-induced platelet activation and aggregation agree with previously published findings describing . Effects of AR-C69931 MX on shear-induced VWF binding, P-selectin surface translocations, and microparticle release. To measure shearinduced VWF binding to single platelets, P-selectin surface translocation, and platelet-derived microparticle release, 480 L of platelet-rich plasma was mixed with 120 L of HEPES-NaCl solution (pH 7.4) containing various concentrations of AR-C69931 MX to achieve final concentrations shown; 400 L of the mixture was exposed to a shear rate of 10 800 s Ϫ1 for 6 minutes; the remaining 200 L was allowed to sit at room temperature. VWF binding was measured by adding 10 L of HEPES-NaCl solution containing FITC-conjugated anti-VWF of LJ-C3 (12.5 g/mL) to a 40-L aliquot of the mixture exposed or not exposed to a shear field. After 15 minutes' incubation at room temperature, the mixtures were diluted by addition of 200 L of HEPES-NaCl solution and stored on ice with protection from light. Quantitative flow cytometry was carried out as described previously. 19 Number of platelets bound with VWF in 10 000 measured (a) and mean number of anti-VWF IgG molecules bound per platelet (d) are shown. Similar procedures were performed to measure shear-induced translocation of P-selectin by adding 10 L of HEPES-NaCl solution containing FITC-anti-P-selectin WGA1 (12.5 g/mL). Number of platelets expressing P-selectin in 10 000 measured (b) and mean number of anti-P-selectin IgG molecules bound/platelet (e) are shown. To measure platelet-derived microparticle release, 10 L of HEPES-NaCl solution containing FITC-conjugated anti-GP Ib␣ (LJ-P3), FITC-conjugated annexin V, and the FITC-conjugated control antibody (T␥: antithyroglobulin) was added to the 40 L of the mixture exposed or not exposed to the shear field. Microparticles carrying the platelet-specific protein GP Ib␣ (c) as well as procoagulant particles bound with annexin V (f) are shown. Results shown are meanϮSEM of 11 experiments. *PϽ0.05, **PϽ0.01. the effects of thienopyridines on shear-induced platelet aggregation and activation 29 -32 and with recently published results with the same P2Y 12 antagonist. 33 However, new and important information regarding the dose-dependent effects of P2Y 12 inhibition on shear-induced platelet reactions has ultimately been addressed in our study. Indeed, our results provide a possible explanation as to why dissociation of once-aggregated platelets under high shear rates occurs after administration of ticlopidine, 32 whereas the maximum extent of shear-induced platelet aggregation remains uninfluenced. Partial P2Y 12 inhibition may cause VWF-mediated aggregation less stable. At relatively high doses (Ͼ5 nmol/L), dose-dependent and saturating effects of AR-C69931 MX, along with the abrogation of inhibition by the exogenous addition of ADP, strongly suggest that the effects of AR-C69931 MX are dependent on its competition with ADP. Moreover, our findings that 50% to 60% of platelet reactions, including platelet aggregation and activation, could be inhibited by a saturating dose of AR-C69931 MX suggest that approximately half of the platelet reactions initiated by the VWF-GP Ib␣ interaction depends on the enhancing role of P2Y 12 stimulation by ADP released from the platelets. Our results are in agreement with the recently published findings of Turner et al, 33 although the latter have also measured stable aggregates present when the shear stress was no longer applied and tested only the highest concentration of AR-C69931 MX in their experiments. Our results, along with previous publications demonstrating partial inhibition of collagen and thrombin-induced platelet activation by clopidogrel, 34 suggest an important role for platelet-derived ADP as a common enhancer of platelet activation.
There still are obvious methodological limitations in our experimental design that limit the application of our results to a clearer understanding of the mechanism of the in vivo antithrombotic effects of thienopyridine antiplatelet agents. Indeed, although the importance of the VWF-mediated mechanism of platelet thrombosis was demonstrated in animal models of arterial thrombosis, 12, 13 the contribution of the VWF-mediated mechanism of platelet thrombus formation is still speculative in the case of human arterial thrombosis. 26 Thus, our idea that thienopyridine antiplatelet agents prevent in vivo arterial thrombosis through inhibition of VWFmediated platelet activation and aggregation is still speculative. Further investigations will be required to demonstrate the role of VWF-mediated mechanisms in the process of in vivo arterial thrombosis. The other important limitation of our study is that the involvement of another important contributing factor for a thrombosis coagulant system was not considered. In the setting of thienopyridine antiplatelet therapy, in addition to platelet thrombosis, fibrin formation might also be influenced, since we have demonstrated that platelet-derived microparticles, which are known to be a major source of platelet procoagulant activity, 20 could be inhibited by P2Y 12 inhibition with the use of AR-C69931 MX.
We used AR-C69931 MX as a specific P2Y 12 antagonist. We have demonstrated the competitive effects of AR-C69931 MX and ADP on platelet activation, as evidenced by PAC1 binding, which detects activated GP IIb/IIIa. 24 Although at least 3 different subtypes of ADP receptors have been cloned, 2,4 previous studies clearly indicate the nature of the specific inhibition of P2Y 12 by AR-C69931 MX, both through biochemical binding assays and by pharmacological studies. 15 AR-C69931 MX inhibits an ADP-induced decrease in cAMP but does not influence other cellular reaction induced by ADP increases, such as Ca 2ϩ influx, intracellular mobilization of Ca 2ϩ , or ADP-induced shape change in platelets. 5 Those results suggested that the effects of AR-C69931 MX on ADP receptors other than P2Y 12 were negligible.
In conclusion, we demonstrated that stimulation of the P2Y 12 receptor plays an important enhancing role in the process of VWF-mediated platelet activation and aggregation occurring under high shear rates. Platelet-derived ADP and its stimulation of P2Y 12 may be a common enhancing system of the platelet response. Figure 6 . Effects of AR-C69931 MX on platelet interaction with immobilized VWF under flow conditions. Blood containing fluorescinated platelets was perfused on the immobilized VWF surface at a wall shear rate of 1500 s Ϫ1 . Platelet interaction with immobilized VWF was detected by epifluorescence videomicroscopy. Sixty consecutive frames of images (corresponding to 2 seconds), converted to black and white by NIH software, were overlayed in 256-scale, gray-scale images; representative results of the 6 experiments performed are shown in the lower panel.
To quantify platelet movement, the total distance moved by the platelets during 2 seconds was measured for each platelet, as shown in the upper panel. Circles and error bars represent meanϮSD values of all the platelet movements measured.
